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Although lysyl oxidase-like 1 (LOXL1) is known as the principal genetic risk factor for pseu-
doexfoliation (PEX) syndrome, a major cause of glaucoma and cardiovascular complications,
no functional variants have been identiﬁed to date. Here, we conduct a genome-wide asso-
ciation scan on 771 German PEX patients and 1,350 controls, followed by independent testing
of associated variants in Italian and Japanese data sets. We focus on a 3.5-kb four-component
polymorphic locus positioned spanning introns 1 and 2 of LOXL1 with enhancer-like chromatin
features. We ﬁnd that the rs11638944:C4G transversion exerts a cis-acting effect on the
expression levels of LOXL1, mediated by differential binding of the transcription factor RXRa
(retinoid X receptor alpha) and by modulating alternative splicing of LOXL1, eventually leading
to reduced levels of LOXL1 mRNA in cells and tissues of risk allele carriers. These ﬁndings
uncover a functional mechanism by which common noncoding variants inﬂuence LOXL1
expression.
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G
laucoma is one of the leading causes of irreversible
blindness worldwide1. It represents a neurodegenerative
disease complex comprising heterogeneous subtypes that
share a common pathogenic pathway, that is, progressive loss of
retinal ganglion cells and optic nerve axons resulting in visual ﬁeld
defects. Within this multifarious disease spectrum, pseudo-
exfoliation (PEX) glaucoma is considered a frequent and
progressive subtype accounting for 25–70% of open-angle
glaucoma and involving a high risk of blindness2,3. It is thought
to be caused by the obstruction of the aqueous humour
outﬂow pathways because of the deposition of extracellular
protein aggregates leading to intraocular pressure elevation and
subsequent glaucomatous optic nerve damage. This abnormally
produced material appears in the course of a common age-related,
generalized disorder of the extracellular matrix termed PEX
syndrome, which affects up to 30% of the elderly population4,5.
Based on the systemic nature of the underlying connective tissue
disorder, PEX syndrome has been associated not only with
glaucoma but also with cardiovascular diseases including
cardiomyopathy and abdominal aortic aneurysms6–8.
Although the incidence of PEX syndrome is clearly inﬂuenced
by environmental factors9, there is a strong genetic component to
the disease10. A genome-wide association study in Scandinavian
populations identiﬁed lysyl oxidase-like 1 (LOXL1) on chromo-
some 15q24.1 as a principal genetic risk factor for PEX syndrome/
glaucoma11, a ﬁnding that has been replicated in multiple
populations worldwide12–16. Two common non-synonymous
protein-coding variants in exon 1, rs1048661G4T (Arg141Leu)
and rs3825942G4A (Gly153Asp), and one intronic variant
(rs2165241T4C), conferring a 20-fold increased risk for PEX,
were initially considered as the causal variants in this
susceptibility locus. However, risk alleles were reversed between
Caucasians and other ethnic populations, that is, Asian and black
South African populations, and—although a biological effect on
LOXL1 protein processing was suggested17—the exact functional
roles of these missense variants in the pathogenesis of PEX have
not yet been ascertained18. ‘Flipping’ of risk alleles and lack of
compelling evidence for their functionality prompted further
search and led to identiﬁcation of additional PEX-associated risk
variants, rs16958477 and rs12914489, in the LOXL1 promoter
region19–21. Recently, Hauser and colleagues identiﬁed
PEX-associated variants at the exon 1–intron 1 boundary of
LOXL1 in black South African, US Caucasian, German and
Japanese patients, which were suggested to modulate the
expression of LOXL1 antisense RNA 1 (LOXL1-AS1), a long
non-coding RNA of LOXL1 (ref. 22). However, these variants had
no effect on LOXL1 expression which is known to be markedly
dysregulated in tissues of PEX patients23–26. Collectively,
a substantial gap remains between the numerous reports
on PEX-associated sequence variants and our understanding of
how these variants contribute to disease.
LOXL1 encodes a member of the lysyl oxidase family of
enzymes (LOX, LOXL 1 to 4), which catalyses the generation of
lysine-derived cross-links in extracellular matrix molecules such
as collagen and elastin27. The currently best known function of
LOXL1 is cross-linking of tropoelastin monomers into elastin
polymers during the formation and maintenance of elastic
ﬁbres28. Current evidence supports a fundamental role for both
LOX and LOXL1 in connective tissue homeostasis and stability.
Their dysregulated expression has been linked to both ﬁbrotic
and elastotic-degenerative connective tissue disorders including
lung emphysema, aneurysms, and pelvic organ prolapse29–32.
Dysregulated expression of LOXL1 also appears to play a key role
in PEX pathogenesis23–26. Notably, reduced expression of LOXL1
in elastin-rich, load-bearing tissues such as the lamina cribrosa
has been suggested as a major susceptibility factor for PEX
glaucoma because of the accompanying elastotic and biome-
chanical tissue alterations24,33, and may be also a predisposing
factor for cardiovascular complications including aortic
aneurysms in PEX patients6–8. Thus, deciphering the mecha-
nisms of LOXL1 regulation is vital to understanding the aetiology
of PEX syndrome and its potentially sight- and life-threatening
complications.
Emerging evidence suggests that intronic variants may have a
role in common disease susceptibility by inﬂuencing transcrip-
tional output of gene expression34. The aim of this study was to
identify potential regulatory variants in the LOXL1 locus and
functionally characterize their impact on LOXL1 expression
regulation. On the basis of a genome-wide association study
in a German cohort of PEX patients we select a cluster of
14 common SNPs within introns 1 and 2 of LOXL1 in complete
linkage disequilibrium (LD) with known variants, and conﬁrm
their association with PEX in European and Asian populations.
Using models of disease-relevant cell types, we provide
experimental evidence for a functional PEX-associated variant,
rs11638944:C4G. Located in a genomic region with regulatory
potential downstream of the canonical LOXL1 promoter, this
variant exerts allele-speciﬁc effects on LOXL1 expression through
differential transcription factor binding and alternative
pre-mRNA splicing in a cell type-speciﬁc manner. Here, we
show that increased transcriptional activity at the risk sequence is
associated with reduced binding of retinoid X receptor alpha
(RXRa) and with enhanced alternative splicing coupled with
nonsense-mediated decay (NMD), which altogether reduces
the levels of LOXL1 mRNA in cells and tissues of risk allele
carriers, underlining a functional link between LOXL1 genetic
variation and regulation of LOXL1 expression.
Results
Selection of LOXL1 candidate variants. To capture potentially
functional regulatory variants in the LOXL1 gene locus, we ﬁrst
performed a genome wide association study using DNA samples
from a German cohort of patients with PEX syndrome/glaucoma
(n¼ 771) and healthy subjects (n¼ 1,350). As expected, we
detected multiple SNPs in high LD at the LOXL1 locus on
chromosome 15 showing strong evidence for association with
PEX, with rs2028386 as example for main association signal
(P¼ 7.62E 22, Fig. 1). Within this locus spanning B19 kb
around exon 1, intron 1, exon 2 and intron 2 of the LOXL1
gene (chr15:74,218,178–74,237,946, GRCh37/hg19), a total of
46 SNPs showed genome wide signiﬁcant association (Po10 8)
with PEX (Fig. 2a). These 46 SNPs include the two non-synon-
ymous variants rs1048661 (p.(Arg141Leu)) and rs3825942
(p.(Gly153Glu)) and the intronic variant rs2165241 identiﬁed in
the original publication by Thorleifsson et al.11
Out of the 46 SNPs, we focused on a cluster of 14 SNPs
showing the most signiﬁcant P-values (Po10 15) (Fig. 2a,
Supplementary Table 1). These 14 SNPs include the known
intronic index SNP rs2165241 and are distributed throughout
intron 1 and the start of intron 2 of LOXL1 (Fig. 2b). In addition,
according to the UCSC genome database, some of these SNPs are
positioned within putative regulatory regions (Fig. 2b), suggesting
that the functional risk variants may reside within this block.
Haplotype analysis including the two index non-synonymous
SNPs conﬁrmed that they are located on the same risk haplotype
(previously deﬁned by the two non-synonymous and the intronic
index SNPs), which is also the more frequent one (ca. 73%) in the
German population (Supplementary Table 2).
Analysis of the same LOXL1 region in an Italian cohort
(421 cases and 1,505 controls) conﬁrmed signiﬁcant association
for these 14 SNPs with PEX syndrome/glaucoma (Table 1,
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Supplementary Table 1, Supplementary Fig. 1). Allelic prevalence
of the PEX-associated risk alleles was about 80% in cases and
about 40% in controls. In addition, all 14 SNPs were signiﬁcantly
associated with PEX syndrome/glaucoma in a Japanese cohort
(1,484 cases and 1,188 controls), although risk alleles were
completely reversed between the two European and Japanese
populations (Table 1). However, in all three cohorts analysed, the
14 selected variants are located within the most frequent
haplotype representing the risk haplotype in each speciﬁc
population as exempliﬁed for the German and Italian cohorts
(haplotype 4, Supplementary Table 2).
Conditional analysis to test for independent association
between the selected SNPs and the two non-synonymous index
SNPs, rs3825942 and rs1048661, revealed no independent
association signal among the 14 SNPs in German and Italian
cohorts (Supplementary Fig. 2).
Correlation of SNPs with LOXL1 tissue expression levels. First,
we assessed whether the 14 SNP risk haplotype correlated
with tissue expression levels of LOXL1. DNA samples of various
post-mortem ocular tissues isolated from 52 individuals with
manifest PEX syndrome/glaucoma and 51 individuals without
PEX were used for genotyping the 14 intronic SNPs (together
with the two non-synonymous SNPs rs1048661 and rs3825942),
while mRNA expression levels of LOXL1 were analysed by
quantitative real time (qRT)-PCR. All 103 samples were stratiﬁed
by their genotypes (risk, non-risk, heterozygous). The 14 SNP risk
haplotype (14sR: GTTCTCGCGTAGCG) in the homozygous
state was overrepresented (64.7%) in ocular tissue samples
derived from PEX patients compared with those (21.2%) obtained
from normal donors without PEX, whereas the non-risk
haplotype (14sN: ACCGCAAGCCGCTA) was clearly under-
represented in PEX samples (5.8%) compared with control
samples (27.6%); heterozygous allele combinations were present
in 29.4% of PEX and in 51.1% of control samples (Fig. 3a). The
presence of the 14 SNP risk haplotype was invariably associated
with the presence of the risk haplotype GG of rs1048661 and
rs3825942 (haplotype 4, Supplementary Table 2), whereas the
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14 SNP non-risk haplotype was associated with haplotypes
TG and GA (haplotypes 1 and 5, Supplementary Table 2) of the
two non-synonymous variants.
Tissue expression levels of LOXL1 were found to correlate with
the 14 SNP haplotype, with signiﬁcantly reduced expression levels
( 40 to 50%, Po0.05) in homozygous risk allele carriers
compared to non-risk allele carriers throughout all ocular tissues
examined, including iris (n¼ 103), ciliary body (n¼ 103)
and lamina cribrosa (n¼ 30) (Fig. 3b–d). Reduced-expression
levels of LOXL1 ( 30%; Po0.001), indicated by a speciﬁc band
at 52 kDa corresponding to a processed form of LOXL1, could be
also conﬁrmed at the protein level for homozygous carriers of the
risk variants (n¼ 6; Fig. 3e, Supplementary Fig. 3). In contrast,
there was no correlation between haplotype and tissue expression
levels of LOXL1-AS1 (Supplementary Fig. 4).
Determination of disease-relevant tissues and cell types. To
analyse the impact of candidate SNPs on transcriptional activity
of LOXL1, we aimed to determine appropriate disease-relevant
cell types, in which the SNPs could exert their regulatory effects.
For that purpose, we compared mRNA expression levels of
LOXL1 in intra- and extraocular tissues in different subsets of
donors with manifest PEX syndrome and age-matched control
subjects carrying the 14 SNP risk and protective haplotypes,
respectively. Using qRT-PCR, we observed signiﬁcantly lower
(30–60%) expression levels of LOXL1 in all tissues of the anterior
eye segment, that is, Tenon’s capsule (n¼ 5), cornea (n¼ 6),
trabecular meshwork (n¼ 17), iris (n¼ 32) and ciliary body
(n¼ 32) (Po0.001) (Fig. 4). In posterior segment tissues, reduced
expression levels of LOXL1 were conﬁned to the lamina cribrosa
(n¼ 20) of PEX eyes, whereas retina, choroid and sclera samples
(n¼ 20 each) showed no differential expression levels between
PEX and control subjects. In addition, aortic wall specimens
(n¼ 5) derived from PEX patients showed also signiﬁcantly
reduced expression levels of LOXL1 compared with control
specimens (Po0.05) (Fig. 4). These differential expression
patterns, which might be explained by tissue-speciﬁc regulatory
mechanisms, are consistent with previous observations of dysre-
gulated tissue expression of LOXL1 as a hallmark of PEX
disease23–25. For functional validation of putative regulatory
variants in LOXL1, we therefore selected human Tenon’s capsule
ﬁbroblasts (hTCF), corneolimbal epithelial cells (hLEPC),
trabecular meshwork cells (hTMC), nonpigmented ciliary
epithelial cells (hNPEC), optic nerve head astrocytes (hONHA)
and aortic smooth muscle cells (hASMC) as disease-relevant and
3T3 ﬁbroblasts and HEK293T cells as unrelated cellular models.
Effect of SNPs on LOXL1 promoter activity in vitro. To analyse
the allele-speciﬁc effects of candidate SNPs on transcriptional
activity of the human LOXL1 promoter, 738 bp fragments
were constructed containing the haplotypes of all 14 risk
(14sR) and non-risk alleles (14sN) and cloned into pGL4.10
luciferase reporter plasmids upstream of a LOXL1 minimal
promoter (nucleotides  1,438/þ 1)35 (Fig. 5a). Haplotype-
speciﬁc reporter constructs were transiently transfected into all
cell types used. Dual luciferase reporter assays showed a
signiﬁcantly lower reporter activity (35–45%; Po0.0001) for the
14sR haplotype constructs compared with the 14sN constructs in
hTCF, hTMC, hNPEC, hONHA and hASMC, but no effect on
LOXL1 promoter activity in hLEPC, HEK293T cells and 3T3
ﬁbroblasts indicating a cell-type speciﬁcity of gene regulation
(Fig. 5b). Further transfections comparing LOXL1 promoter
activity in hTCF derived from different donors (ageo20 years vs.
age465 years, presence vs. absence of PEX, German vs. Japanese
origin) did not show any statistically signiﬁcant differences in the
decrease of reporter activity by the 14sR/N constructs between
subgroups precluding any modulating effect of age, ethnicity or
PEX disease in this cell model (Supplementary Fig. 5A).
Next, several deletion constructs of pGL4.10-LOXL1-14sR/N
were transfected into hTCF showing that the reduction in LOXL1
promoter activity (41%; Po0.0001) was achieved by constructs
(14sR11–14) including the risk haplotype of the distal four SNPs
11–14. In contrast, constructs including SNPs 1–5 (14sR1–5) or
SNPs 6–10 (14sR6–10) failed to differentially affect LOXL1
promoter activity in hTCF (Fig. 5a,c). Control transfections with
empty basic pGL4.10 vector and basal LOXL1 promoter construct
showed only little background luciferase activity and no obvious
enhancer activity over core promoter activity (Fig. 5c). Thus,
haplotype constructs served as useful indicator of a potential
regulatory region including SNPs 11–14 of LOXL1.
To ultimately assess a difference in transcriptional activities
between individual SNPs included within the effective pGL4.10-
LOXL1-14sR/N11-14 constructs, we generated eight distinct
reporter plasmids containing each of the four risk or non-risk
alleles of SNPs 11–14 in their unaltered genomic context and
transiently transfected them into various cell types. Statistically
signiﬁcant allele-dependent effects on reporter activity were
observed for SNP 12 and SNP 14 in a cell type-speciﬁc manner in
Table 1 | Association analysis for the 14 selected SNPs in three different populations.
SNP Chr Pos Ass-
all_DEþ IT
German (771 Patients/1,350
Controls)
Italian (421 Patients/1,505
Controls)
Japanese (1,484 Patients/1,188 Controls)
P value_DE OR (95%CI)_DE P value_IT OR (95%CI)_IT Ass-all_JAP P value_JAP OR (95%CI)_JAP
rs8023330 15 74220599 G 3.20E 18 2.78 (2.42–3.18) 3.75E 29 2.93 (2.94–4.14) A 2.06E 35 4.73 (3.63–6.16)
rs1550436 15 74221157 T 2.09E 18 2.79 (2.43–3.19) 5.23E 29 2.95 (2.96–4.16) C 2.06E 35 4.73 (3.63–6.16)
rs2165241 15 74222202 T 1.22E 21 3.02 (2.62–3.47) 1.54E 31 3.85 (3.22–4.59) G 3.95E 35 4.69 (3.60–6.11)
rs28588430 15 74223430 C 1.30E 21 3.02 (2.62–3.47) 1.59E 31 3.85 (3.19–4.49) G 1.48E 35 4.75 (3.65–6.18)
rs28617339 15 74223571 T 1.27E 21 3.02 (2.62–3.47) 1.58E 31 3.85 (3.19–4.49) C 1.48E 35 4.75 (3.65–6.18)
rs4886778 15 74225388 C 8.30E 22 3.1 (2.69–3.57) 1.54E 32 3.95 (3.28–4.73) A 1.53E 136 6.85 (5.73–8.20)
rs8027022 15 74226138 G 9.74E 22 3.1 (2.69–3.57) 2.13E 32 3.95 (3.28–4.73) A 2.79E 136 6.84 (5.72–8.18)
rs2028386 15 74226708 C 7.62E 22 3.1 (2.69–3.57) 2.41E 32 3.95 (3.28–4.74) G 7.87E 136 6.84 (5.72–8.18)
rs4337252 15 74226765 G 8.23E 22 3.1 (2.69–3.57) 1.38E 32 3.95 (3.25–4.59) C 7.87E 136 6.84 (5.72–8.18)
rs12440667 15 74231439 T 1.55E 18 2.78 (2.43–3.19) 1.29E 29 3.55 (2.98–4.22) C 2.38E 35 4.71 (3.62–6.13)
rs12905253 15 74232437 A 1.55E 18 2.78 (2.43–3.19) 1.23E 29 3.55 (2.99–4.22) G 1.90E 35 4.73 (3.64–6.15)
rs11638944 15 74234082 G 1.45E 18 2.78 (2.43–3.19) 1.16E 29 3.55 (2.99–4.22) C 1.90E 35 4.73 (3.64–6.15)
rs12441130 15 74234902 C 8.01E 19 2.83 (2.47–3.25) 5.88E 31 3.65 (3.05-4.36) T 5.05E 137 6.89 (5.76–8.24)
rs11631579 15 74235704 G 1.41E 18 2.78 (2.43–3.19) 1.20E 29 3.54 (2.98–4.21) A 1.90E 35 4.73 (3.64–6.15)
Ass-all, associated allele; Chr, chromosome; DE, German; IT, Italian; JAP, Japanese; OR, odds ratio; Pos, position based on UCSC Genome Browser (hg19).
All genotypes were imputed from GWAS data. A logistic regression model adjusted for age and gender was used for the German and Italian cohort, and adjusted for the ﬁrst six principal components of
genetic stratiﬁcation for the Japanese cohort.
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hTCF (Fig. 5d), hASMC (Fig. 5e), hTMC, hNPEC and hONHA
but not in HEK293T cells (Supplementary Fig. 5B). However, in
contrast to the haplotype constructs, the risk alleles increased
transcriptional activity compared to non-risk alleles (SNP 12:
35–75%, Po0.005; SNP 14: 25–45%, Po0.05), and the risk
sequence of SNP 12 even enhanced transcription up to 120%
(Po0.005) from minimal core promoter (Fig. 5d,e). From these
ﬁndings, which we believe to reﬂect the true function of these
variants in their genomic context better than the engineered
haplotypic combinations, we conclude that the risk allele of SNP
12 located at the end of intron 1 of LOXL1 has enhancer-like
function increasing transcriptional activity compared to non-risk
alleles in disease-relevant cell types.
Effect of SNPs on LOXL1 transcriptional activity in vivo. Since
reporter-based assays fail to account for the native chromatin
context of the regulatory region, we analysed allele-speciﬁc effects
of intronic SNPs 11–14 on LOXL1 transcriptional activity in
heterozygous cell lines by allelic expression imbalance assay,
which is considered a robust in vivo measure of cis-regulatory
variants. To discriminate between the two alleles, we used a
highly sensitive Taqman SNP Genotyping Assay available for
SNP 13 (rs12441130:T4C) serving as a marker SNP for cDNA
generated from pre-mRNA transcribed from each chromosomal
allele and genomic DNA from the same samples as a control. Pre-
mRNA analysis from hTCF (n¼ 15) heterozygous at all four
SNPs 11–14 showed distinct allelic imbalance compared
to genomic DNA with an allelic shift towards the risk allele
C (Fig. 6a). The relative abundance of the risk allele C was
threefold increased over that of the non-risk allele T (Po0.0001).
These changes in relative allelic rates of transcription could be
conﬁrmed by RNA polymerase II (Pol II)-ChIP, which was
performed with cross-linked chromatin from heterozygous hTCF
(n¼ 2) using antibodies against Pol II, histone H3 and acetylated
histone H3K26Ac (positive controls), and non-immune rabbit
IgG (negative control), and allele-speciﬁc Taqman SNP Genotyp-
ing Assay for rs12441130 (SNP 13) (Fig. 6b). Almost twofold
increased relative amounts of DNA containing the risk alleles
were precipitated with the Pol II antibody (Fig. 6b), suggesting
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Figure 3 | Correlation of LOXL1 risk variants with LOXL1 tissue expression levels. (a) Frequency of the homozygous risk (14sR), non-risk (14sN) and
heterozygous (Het) haplotypes formed by the 14 selected SNPs in PEX (n¼ 52) and control (n¼ 51) samples. (b) Genotype-correlated expression levels of
LOXL1 mRNA in iris tissue samples (n¼ 103) obtained from PEX (n¼ 52) and control (n¼ 51) patients using real time PCR technology; data are presented
as mean values±s.d. (c) Genotype-correlated expression levels of LOXL1 mRNA in ciliary body tissue (n¼ 103). (d) Genotype-correlated expression levels
of LOXL1 mRNA in lamina cribrosa specimens (n¼ 30). (e) Western Blot analysis of LOXL1 protein expression in iris specimens (n¼ 18) according to LOXL1
genotypes; speciﬁc bands indicating LOXL1 appear at 52 kDa. Equal loading of samples was veriﬁed by immunodetection of -actin, and LOXL1 expression
levels were normalized to -actin expression. Densitometry analysis of band intensities shows mean values±s.d. of three independent experiments
(n¼6 samples for each genotype) (the two other Western blots are shown in Supplementary Fig. 3) (*Po0.05; **Po0.001; ***Po0.0001; unpaired
two-tailed Student’s t-test).
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that the transcriptional activity at the risk sequence is increased
over that of the non-risk sequence. Antibodies against histone
H3 did not show any difference between both alleles. Fidelity of
the ChIP assay was conﬁrmed by PCR of immunoprecipitated
complexes and by qPCR showing sixfold enrichment of Pol II
over IgG control (Fig. 6b).
In view of the fact that the risk haplotype correlated with
reduced total LOXL1 mRNA expression levels in post-mortem
tissue samples (Fig. 3b–d), as a next step we examined whether
increased transcriptional activity at the risk sequence is associated
with post-transcriptional regulation of steady-state gene expres-
sion levels by alternative pre-mRNA splicing. ENSEMBL database
indicated the presence of an alternative transcript (LOXL1-002:
ENST00000566011; Havana project, version 1: transcript
OTTHUMT00000419872.1), which is characterized by selective
inclusion of an additional exon (E1A) between exon 1 and exon 2
of the LOXL1 gene introducing a premature termination codon in
exon 2 via frameshift (Fig. 7a). The premature termination codon
is localized 100 nucleotides upstream of the exon 2–exon 3
junction thus fulﬁlling the requirements (450 nucleotides
upstream of an exon/exon junction complex) for a NMD target36.
Transcript levels of LOXL1-E1A were determined by qPCR using
exon 1-speciﬁc forward and E1A-speciﬁc reverse primers
(Supplementary Table 3.2) and identity of qPCR fragments was
conﬁrmed by sequence analysis (Euroﬁns Genomics). Treatment
of hTCF with the protein synthesis inhibitor puromycin, which
is known to selectively stabilize NMD transcripts36, increased
the level of LOXL1-E1A ﬁvefold (Po0.001), whereas levels
of wild-type LOXL1 mRNA were decreased fourfold (Po0.0001)
(Fig. 7b). In contrast, levels of LOXL1-AS1 were not signiﬁcantly
changed by puromycin. RT-PCR using primers spanning
E1A (Supplementary Table 3.3) produced a prominent band
for wild-type LOXL1 at 147 bp and a weaker band for
LOXL1-E1A at 331 bp after treatment with puromycin in hTCF
cell lines (Fig. 7b). Genotype–phenotype correlations showed
that hTCF cell lines homozygous for the risk allele C of the
marker SNP 13 express signiﬁcantly higher constitutive levels of
LOXL1-E1A (1.75-fold; Po0.05) and signiﬁcantly lower levels of
wild-type LOXL1 mRNA ( 1.65-fold; Po0.001) than cell
lines homozygous for the protective allele T, whereas levels of
LOXL1-AS1 did not correlate with the genotype of cells (Fig. 7c).
To ultimately conﬁrm that LOXL1-E1A is a direct target of
NMD, we inhibited NMD through transient knockdown of UPF1
(Up Frame Shift Protein 1), a central component of the NMD
pathway36, leading to a signiﬁcant increase in LOXL1-E1A in
hTCF (Fig. 7d).
From these experiments we conclude that alternative splicing
of LOXL1 pre-mRNA coupled with NMD is signiﬁcantly
inﬂuenced by the genotype of SNPs 11–14 located in close
proximity to the splice site (Fig. 7a). Higher rates of NMD lead to
reduced steady-state levels of LOXL1 in risk allele carriers
compared to non-risk allele carriers. This common mechanism of
post-transcriptional regulation of gene expression36 may explain
downregulation of total LOXL1 expression levels in cells and
tissues of risk allele carriers despite of increased transcriptional
activity at the risk sequence.
Effect of SNPs on transcription factor binding afﬁnity. Since
transcription factors have been found as primary mediators of
sequence-speciﬁc regulation of gene expression in a context-
dependent manner, we performed electrophoretic mobility
shift assays (EMSAs) to determine allele-speciﬁc differences
in transcription factor–DNA interactions. Using biotinylated
228–292 bp DNA fragments containing the risk and non-risk
alleles of individual SNPs 11–14 and nuclear extracts from
disease-relevant cell types (hTMC, hNPEC, hTCF), all probes
yielded one or two speciﬁc shifted bands, which could be
competitively inhibited by unlabelled oligonucleotides up to 100%
(Supplementary Fig. 6). Quantitative analysis of the shifted bands
relative to the unshifted bands from 5 independent experiments
revealed that the risk sequences of rs12905253 (SNP 11) and
rs12441130 (SNP 13) showed greater binding afﬁnity to nuclear
proteins (35–57%; Po0.05) compared to the non-risk sequences.
In contrast, the risk sequences of rs11638944 (SNP 12) and
rs11631579 (SNP 14) showed lower binding efﬁciency ( 25%)
than the non-risk sequences. These allelic differences were
statistically most signiﬁcant (Po0.005) for SNP 12-containing
probes, which also showed the greatest binding afﬁnity to nuclear
proteins of all probes (Supplementary Fig. 6). No allele-speciﬁc
differences were observed with nuclear extracts from hLEPC,
HEK293T and 3T3 cells (Supplementary Fig. 7).
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Figure 4 | Determination of pathophysiologically relevant tissues and cell types. Expression of LOXL1 mRNA in ocular and extraocular tissues derived
from normal human donors (control) and donors with manifest PEX syndrome using real-time PCR technology. The expression levels were normalized
relative to GAPDH. Expression levels were signiﬁcantly reduced in Tenon’s capsule (n¼ 5), cornea (n¼ 6), trabecular meshwork (n¼ 17), iris (n¼ 32),
ciliary body (n¼ 32), lamina cribrosa (n¼ 20) and aortic wall (n¼ 5) from PEX patients compared to controls, and were not different in retina, choroid and
sclera (n¼ 20 each); (data represent mean values±s.d.; *Po0.05, **Po0.001, ***Po0.0001; unpaired two-tailed Student’s t-test).
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In silico analysis using rSNP-MAPPER software37 identiﬁed
several putative transcription factor binding sites potentially
affected by the sequence variant differences. Among sites with
high predicted difference for an allelic effect on binding were:
LXRa:RXRa, myogenin/NF-1, Roaz, ZID, NR2F1, NFkB,
PPARa:RXRa and HNF-4a in the region of rs11638944
(SNP 12) (Supplementary Table 4, Supplementary Fig. 8A).
Supershift assays using DNA probe S12R and antibodies against
candidate transcription factors did not show any speciﬁc binding
of antibodies against LXRa, myogenin, NF-1, Roaz, NR2F1,
NFkBp50, NFkBp65 (RELA), PPARa, PPARg and HNF-4a,
whereas antibodies against RXRa (retinoid X receptor alpha) and
ZID (zinc ﬁnger protein with interaction domain) disrupted the
protein–DNA complexes in EMSA experiments and produced
supershifted bands (Fig. 8a). Because mRNA expression of lysyl
oxidases is known to be regulated by retinoic acid38, we further
focused on the nuclear retinoic acid receptor RXRa, which
mediates retinoic acid-induced gene activation. Comparison of
risk and non-risk sequences of all four SNPs in supershift
experiments with anti-RXRa antibody showed increased
supershifted band densities for the risk sequences of SNP 11
and SNP 13 by 25–150%; differences were, however, statistically
not signiﬁcant. In contrast, binding afﬁnity of RXRa antibody to
the risk sequences of SNP 12 ( 26%; Po0.001) and SNP 14
( 17%; NS) was decreased compared to the non-risk sequences
(Fig. 8b, Supplementary Fig. 9), although predicted binding scores
were higher for the risk than for the non-risk sequences of SNP
12 (Supplementary Table 4, Supplementary Fig. 8B).
In view of this discrepancy, speciﬁc binding of both recombi-
nant RXRa protein fragment containing the DNA-binding domain
(in a concentration-dependent manner) and full-length RXRa
protein was used as positive control and resulted in shifted bands
corresponding to their respective molecular sizes, whereas
recombinant RXRa fragment containing the ligand-binding
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Figure 5 | Effects of risk variants on LOXL1 promoter transcriptional activity in vitro. (a) Reporter constructs used in transfection experiments outlining
the 14 S/R constructs comprising all 14 SNPs ﬂanked by 51 bp of genomic DNA sequences each (top) and three deletion constructs comprising SNPs 1–5,
SNPs 6–10 and SNPs 11–14, respectively (bottom). (b) Dual luciferase reporter assays demonstrating regulatory activity of 14 SNP risk (14sR) and non-risk
(14sN) haplotypes in human Tenon‘s capsule ﬁbroblasts (hTCF), trabecular meshwork cells (hTMC), nonpigmented ciliary epithelial cells (hNPEC), optic
nerve head astrocytes (hONHA), aortic smooth muscle cells (hASMC), limbal epithelial cells (hLEPC), 3T3 ﬁbroblasts and HEK293T cells. Results are
expressed as the ratio of Fireﬂy luciferase to Renilla luciferase; the transcriptional activity of the non-risk sequence was set at 100%. (c) Regulatory activity
of three deletion constructs (SNPs 1–5, 6–10 and 11–14) in hTCF compared with the basal LOXL1 promoter activity; the transcriptional activity of the empty
pGL4.10 vector was set at 100%. (d,e) Activity assays using reporter plasmids containing each of the four risk or non-risk alleles of individual SNPs 11, 12, 13
and 14 compared with the basal LOXL1 promoter activity in hTCF (d) and hASMC (e); the transcriptional activity of the empty pGL4.10 vector was set at
100% (data represent mean values±s.d. of ﬁve independent experiments; *Po0.05; **Po0.005; ***Po0.0001; unpaired two-tailed Student‘s t-test).
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domain was not effective (Supplementary Fig. 10A). A biotinylated
control oligonucleotide containing a RXR consensus binding site
was further used as positive control in EMSAs using hTCF, hTMC
and hNPEC nuclear extracts and resulted in shifted bands which
could be competitively inhibited by unlabelled probes (Suppleme-
ntary Fig. 10B). Moreover, RXRa binding to SNP 12 region
in vivo was veriﬁed by RXRa-ChIP, which was performed with
cross-linked chromatin from hTCF (n¼ 2) using two different
antibodies against RXRa, H3 (positive control) and non-immune
IgG (negative control). Fidelity of the ChIP assay was conﬁrmed by
PCR of immunoprecipitated complexes and by qPCR showing
fourfold enrichment of RXRa over IgG control (Fig. 9a). Because a
speciﬁc Taqman Genotyping Assay for SNP 12 was not
commercially available to assess allele-speciﬁc differences in RXRa
binding, we performed luciferase assays using both risk and
non-risk genotypes of SNP 12 without or with co-transfection of
RXRa-speciﬁc siRNA in hTCF. These experiments showed that the
allele-speciﬁc differences in transcriptional activity were abolished
by knockdown of RXRa (Fig. 9b), providing additional evidence
for an allele-speciﬁc binding of RXRa and a role for this
transcription factor in LOXL1 gene regulation.
RXRa was found to be expressed in nuclear fractions of all
disease-relevant cell types including hTCF, hTMC, hNPEC and
hASMC (Fig. 9c). siRNA-mediated knockdown of RXRa in hTCF
resulted in a signiﬁcant upregulation (40%; Po0.005) of LOXL1
mRNA expression compared to mock-transfected control cells
(Fig. 9d). Stimulation with all trans-retinoic acid (2 mM for 24 h)
signiﬁcantly increased RXRa expression but reduced LOXL1
expression in disease-relevant cell types, such as hTCF and
hASMC, compared with non-treated controls (Fig. 9e). These
data provide direct evidence that RXRa inﬂuences LOXL1
expression by functioning as a transcriptional repressor.
Sequence inspection of the DNA probes using rSNP-MAPPER
software predicted binding motifs for RXRa:LXRa and RXRa:P-
PARa heterodimers in the region of SNP 12, which overlapped
the SNP position (Supplementary Fig. 8B). However, antibodies
against known heterodimeric partners for RXRa, that is, RARa,
LXRa/b, PPARa/g, VDR, TRa/b and ERa, did not result in
supershifted bands (Fig. 8a, Supplementary Fig. 11) suggesting
either homodimeric RXRa binding or another not yet identiﬁed
heterodimeric binding partner. Nevertheless, the present ﬁndings
identiﬁed RXRa as candidate transcription factor showing
signiﬁcantly reduced binding to the risk sequence of
rs11638944, which may be important for retinoic acid sensitivity
of this regulatory region and for the suppressive effect of retinoic
acid on LOXL1 expression.
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Figure 6 | Effects of risk variants on LOXL1 transcriptional activity in vivo. (a) Scatter plot of TaqMan-based allelic discrimination of the LOXL1 SNP 13
(rs12441130). The genotypes of hTCF homoyzgous for the risk (C) or non-risk (T) alleles are shown in relation to genomic DNA and pre-mRNA containing
cDNA of heterozygous hTCF cell lines (n¼ 15). Relative abundance of risk allele C over non-risk allele T in heterozygous hTCF cell lines (n¼ 15); expression
level of T allele was set at 100%. (b) ChIP assay for RNA polymerase II (Pol II) binding at rs12441130 (SNP13)-containing region of LOXL1 in heterozygous
hTCF cell lines (n¼ 2) using antibodies against Pol II, histone H3 and acetylated histone H3K27Ac (positive controls), and non-immune IgG
(negative control); input represents total chromatin applied for immunoprecipitation. Allele-speciﬁc ChIP-qPCR analysis for Pol II chromatin binding and
histone H3 is shown (left); expression levels of the non-risk allele Twere set at 100%. DNA isolated from immunoprecipitated complexes was analysed on
2% agarose gel (top right) and by qPCR (bottom right) with primers speciﬁc for the SNP13 region producing a 121 bp PCR fragment (arrow). Data are
expressed as per cent of input (Lane 1: hTCF 1, lane 2: hTCF 2, lane M: DNA marker, lane N: primer control without chromatin).
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Discussion
Genetic and pathogenetic analyses have conﬁrmed a highly
signiﬁcant and direct role for LOXL1 in the pathophysiology
of PEX syndrome and its associated ocular and systemic
complications. Dysregulated tissue expression of LOXL1 has
been shown to be a hallmark of PEX syndrome, contributing to
disease development and predisposing to ocular and systemic
complications23–26. Reduced tissue expression levels of LOXL1
have been related to pronounced structural elastotic and
biomechanical alterations of elastin-rich connective tissues, such
as the lamina cribrosa and blood vessel walls, thereby increasing
the risk for pressure-induced optic nerve damage and
cardiovascular complications24,33. Accordingly, our group and
others have described a signiﬁcant association between PEX and
systemic disorders of elastic tissues, that is, aortic aneurysms,
coronary artery ectasia, renal artery stenosis and pelvic organ
prolapse6–8,39–42. Changes in LOXL1 gene expression have been
observed in many other conditions, including aging43,44 and
disorders involving weakening of elastic connective tissues45–47.
Although the discovery of LOXL1 as the principal genetic risk
factor for PEX dates back to 2007 (ref. 11) and has been
subsequently replicated by multiple studies in various
geographical populations12–16, it is currently not known how
associated variants contribute to disease. So far, no single causal
variant has been identiﬁed. In fact, the precise analysis of the
LOXL1 locus is still at a rudimentary stage, and the translation of
genetic ﬁndings into molecular mechanisms remains a hitherto
unmet need and challenge. Here, we provide experimental
evidence that a common risk variant, located in a genomic
region of intron 1 of LOXL1 with regulatory potential, exerts
a cis-acting effect on LOXL1 expression, mediated by differential
transcription factor binding and differential alternative
pre-mRNA splicing in a cell type-speciﬁc manner. We show
that increased transcriptional activity at the risk sequence is
associated with reduced binding of RXRa and with increased
levels of an alternatively spliced LOXL1 transcript sensitive to
NMD, possibly by allele-speciﬁc interaction with splicing factors,
and, seemingly contradictory, with decreased levels of normal
LOXL1 mRNA in cells and tissues of risk allele carriers.
However, signiﬁcant inconsistencies in pre-mRNA and mRNA
expression levels have been described for many genes and
indicate a post-transcriptional mode of regulation frequently
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Figure 7 | Effects of risk variants on LOXL1 alternative splicing. (a) The two LOXL1 transcripts (LOXL1, LOXL1-E1A) seen in the alignment with position of
SNPs 11–14; exons are indicated by numbers (E1–E7), the additional exon included in the alternative transcript is indicated as E1A; the location of stop
codons is marked by vertical lines. (b) Expression levels of transcripts LOXL1-E1A, LOXL1 and LOXL1-AS1 in hTCF cell lines (n¼ 16) without (control) or after
treatment with puromycin (200ngml 1 for 10 h) using real-time PCR technology (left); hTCF were either homozygous for the risk (n¼8) or non-risk
(n¼8) alleles for SNPs 1–14. PCR from LOXL1 and LOXL1-E1A transcripts without and after puromycin treatment of hTCF (n¼ 3) using primer pairs spanning
exon 1A (right; lane M: DNA marker). (c) SNP rs12441130-correlated expression levels of transcripts LOXL1-E1A, LOXL1 and LOXL1-AS1 in hTCF cell lines
homozygous for the risk alleles (C/C) (n¼ 8) or non-risk alleles (T/T) (n¼8) using real-time PCR technology. (d) Real-time PCR analysis of UPF1 and
LOXL1-E1A in hTCF cell lines (n¼4) transfected with UPF1-speciﬁc siRNA or scrambled control siRNA; expression levels were normalized relative to
GAPDH (data represent mean values±s.d.; *Po0.05; **Po0.001; ***Po0.0001; unpaired two-tailed Student‘s t-test).
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involving the NMD pathway36,48. The NMD pathway is a
common translation-dependent mRNA degradation pathway that
controls levels of alternatively spliced unproductive mRNA
variants to regulate gene expression. In the case of constitutive
unproductive splicing, which may be inﬂuenced by sequence
variation close to splice sites, the combined effect of alternative
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Figure 8 | Allele-speciﬁc transcription factor binding. (a) Supershift assays with DNA fragments containing the risk sequence of rs11638944 (S12R),
nuclear extracts from human trabecular meshwork cells, and speciﬁc antibodies against candidate transcription factors liver X receptor (LXR)a/, retinoid
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splicing coupled to NMD reduces total message abundance by a
more or less constant factor, which has been also observed in cells
and tissues of risk allele carriers in the present study. Moreover,
coupling of alternative splicing and NMD has been reported as
a general mode of controlling gene expression in a dynamic,
developmental stage- and cell type-speciﬁc manner, promoting
cellular adaptation in response to a variety of cellular stresses49,50.
Preliminary data have shown that LOXL1-E1A activity is
modulated by distinct forms of stressors and metabolites,
including oxidative stress, to regulate LOXL1 gene expression.
Thus, we have identiﬁed allele-speciﬁc effects on LOXL1
gene regulation at the transcriptional (RXRa binding),
co-transcriptional (pre-mRNA splicing) and post-transcriptional
(mRNA decay) level, together resulting in a downregulation
(40–50%) of LOXL1 gene expression levels in cells and tissues of
risk allele carriers. The ﬁndings are further supported by known
functions of RXRa generally behaving as constitutive repressor
of transcription in the absence of ligand51 through interaction
with a diverse repertoire of canonical and non-canonical
binding elements52.
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Figure 9 | RXRa inﬂuences LOXL1 expression by functioning as a transcriptional repressor. (a) ChIP assay for RXRa binding at rs11638944 (SNP12)-
containing region of LOXL1 in heterozygous hTCF cell lines (n¼ 2) using two different antibodies against RXRa (1: D-20, 2: F-1), histone H3 (positive
control) and non-immune IgG (negative control); input represents total chromatin applied for immunoprecipitation. DNA isolated from immunoprecipitated
complexes was analysed on 2% agarose gel (left) and by qPCR (right) with primers speciﬁc for the SNP12 region producing a 148 bp PCR fragment (arrow).
Data are expressed as per cent of input (Lane 1: hTCF 1, lane 2: hTCF 2, lane M: DNA marker, lane N: primer control without chromatin). (b) Dual luciferase
reporter assays using reporter plasmids containing risk (12R) and non-risk (12N) genotypes of SNP 12 alone or co-transfected with RXRa-speciﬁc siRNA in
human Tenon’s capsule ﬁbroblasts (hTCF) compared with the basal LOXL1 promoter activity. Results are expressed as the ratio of Fireﬂy luciferase to Renilla
luciferase; the transcriptional activity of the empty pGL4.10 vector was set at 100% (data represent mean values±s.d. of three independent experiments;
*Po0.005; unpaired two-tailed Student’s t-test). (c) Western blot analysis of RXRa expression in cytoplasmic and nuclear protein fractions of human
Tenon’s capsule ﬁbroblasts (hTCF), trabecular meshwork cells (hTMC), nonpigmented ciliary epithelial cells (hNPEC) and aortic smooth muscle cells
(hASMC) at B60 kDa (C, cytoplasmic fraction; N nuclear fraction). (d) Real-time PCR analysis of RXRa and LOXL1 mRNA in hTCF cell lines (n¼4)
transfected with RXRa-speciﬁc siRNA or scrambled control siRNA; expression levels were normalized relative to GAPDH. (e) Real-time PCR analysis of
RXRa and LOXL1mRNA without and with stimulation by 2 mM all trans-retinoic acid for 48 h in hTCF and hASMC; expression levels were normalized relative
to GAPDH (data represent mean values±s.d.; *Po0.05, **Po0.001, ***Po0.0001; unpaired two-tailed Student’s t-test.
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Although high LD in the region makes it difﬁcult to
distinguish the polymorphism(s) driving the causal association,
rs11638944:C4G (SNP 12) showed most signiﬁcant enhancer-
like activities and allelic effects on transcription factor binding,
suggesting that rs11638944 functions as primary cis-acting
expression quantitative trait locus (eQTL) of LOXL1. The SNP
is located in a region of intron 1 with enhancer-like chromatin
features, such as speciﬁc histone modiﬁcations marking active
enhancers (H3K27Ac), DNase I hypersensitivity sites and trans-
cription factor binding sites (Supplementary Fig. 8A), which are
compatible with predictions of functional regulatory elements53.
Further conﬁrmation arises from eQTL data sets, such as the
BROAD Institute’s GTEx portal (www.gtexportal.org/), revealing
a signiﬁcant eQTL for this SNP in pituitary tissue. These ﬁndings
are also in line with current concepts of regulatory variants
affecting gene expression as major contributors to common
disease risk34. Disease-associated variants in noncoding regions,
particularly those that map to enhancer elements speciﬁc to
disease-relevant cell types, have been estimated to explain a
greater proportion of the heritability for some disorders than
variants in coding regions54.
There are, however, some limitations of the study.
1. The PEX-associated risk alleles were identical in two European
populations, but completely reversed in Japanese populations
(Table 1), which seems to be a principle for all LOXL1 variants
identiﬁed so far21,55–58. Allelic reversal in Japanese patients
may be explained by allelic heterogeneity, the existence of
different SNPs tagging the same not yet identiﬁed causal
variant in all populations, or multi-locus effects implying a
change in LD pattern between the two markers in two
populations of different ancestry59. Such ﬂip–ﬂop associations,
probably caused by multi-locus effects, have already been
reported for other complex diseases including Alzheimer’s
disease and autism as well as obesity60,61. SNP function may be
also context-dependent and the cause of the disparity between
European and Japanese populations may be related to a
combination of genetic architecture and environmental risk
factors causing a similar phenotype. Although this enigma
cannot be solved by the present study, potential regulatory
differences at the DNA level as well as potential differences in
LOXL1 expression quantitative phenotypes and their relation
to variations in PEX prevalence between European and
Japanese populations will be the subject of future studies.
2. Other potential mechanisms that are critical to regulation of
gene expression and may be modulated by genetic variation,
such as epigenetic modiﬁcations, disruption of chromatin
interactions, action of noncoding RNAs, and mRNA proces-
sing and stability have not been investigated in this analysis.
DNA hypermethylation of the LOXL1 promoter has been
shown to occur in PEX patients26 and reported to
downregulate LOXL1 expression in skin ﬁbroblasts in a case
with cutis laxa35 and in human bladder cancer cells62. A
functional SNP, rs45008784A4C, in the promoter region of
LOXL1 impacting gene expression has been identiﬁed, but was
not associated with disease (pelvic organ prolapse) and did
not reveal any differential transcription factor binding63.
Hauser et al.22 have identiﬁed a region of peak association at
the LOXL1 exon 1–intron 1 junction, which contains a
promoter of a long non-coding antisense RNA, LOXL1-AS1,
which is modulated by a haplotype of three functional risk
variants associated with PEX in a South African population.
However, this region does not enhance LOXL1 promoter
activity in vitro and has not been functionally linked to PEX
pathophysiology in vivo, although the authors suggested that
dysregulated expression of LOXL1-AS1 plays a role in PEX
pathogenesis, particularly in cellular response to stresses.
Despite the limitations mentioned above, we were able to
establish a functional link between LOXL1 genetic variation and
regulation of the expression of LOXL1 through identiﬁcation of
an eQTL in intron 1 explaining part of the genetic variance of the
LOXL1 expression phenotype. The present ﬁndings also highlight
the importance of context-speciﬁcity in resolving the mechanisms
of action of regulatory variants. We further suggest molecular
mechanisms by which sequence variation modulates transcrip-
tional output on two levels of gene expression regulation, that
is, differential transcription factor binding and alternative
pre-mRNA splicing, and identiﬁed the transcription factor RXRa
and regulated coupling of alternative splicing and NMD as a
mechanism involved in LOXL1 gene regulation; their precise
functional roles and mechanisms of action will be scrutinized in
future studies. Since we were not able to untangle the ﬂipped
allele phenomenon observed between Caucasian and Asian
populations, targeted resequencing of the risk haplotype in both
populations and further context-speciﬁc research is required to
determine how LOXL1 variants actually contribute to PEX
pathophysiology. Ultimately, the functional translation of genetic
information to the tissue level and a detailed understanding of
LOXL1 gene regulation will guide improved risk prediction and
future treatment strategies for a common disease and its
potentially sight- and life-threatening complications.
Methods
Studied groups and study approval. This study utilized three case–control data
sets from two European (German, Italian) and one Asian (Japanese) cohort. Ethics
approval for this study was obtained from the Institutional Review Boards of the
Medical Facultiy of the University of Erlangen-Nu¨rnberg (Germany), the Medical
Faculty of the University of Siena (Italy), the Monfalcone Hospital (Italy), Hayashi
Eye Hospital (Fukuoka), Mizoguchi Eye Hospital (Nagasaki), Oita University
Faculty of Medicine, Kyoto University Graduate School of Medicine, Ideta Eye
Hospital (Kumamoto), the Sing Health Centralised Institutional Review Board
Singapore as well as three sites in Miyazaki, that is, Shinjo Eye Clinic, Miyata Eye
Hospital and Ozaki Eye Hospital. All participants had given written informed
consent, and investigations were performed in accordance with the principles of
the Declaration of Helsinki. All patients with PEX syndrome showed manifest
PEX material deposits on anterior segment structures in mydriasis on slitlamp
biomicroscopy. Secondary open-angle glaucoma due to PEX was deﬁned, if
elevated intraocular pressure, characteristic visual ﬁeld defects and characteristic
optic disc atrophy were observed in the presence of an open chamber angle and
typical PEX deposits. Healthy population-based controls were recruited from the
same geographic areas as the PEX patients64–67.
To investigate the association between PEX and SNPs in chromosomal
region [chr15: 74,218,178-74,237,946 (hg19)] encompassing exon 1, intron 1,
exon 2 and part of intron 2 of LOXL1 (19 kb), we used SNP array-derived data
(Affymetrix Genome-Wide Human SNP Array 6.0) of 771 German patients with
PEX (PEX syndrome: 309; PEX glaucoma: 462) and 1,350 healthy individuals from
a population-based control cohort (KORA). These patients and controls formed
the discovery part of our study. To replicate association results of selected SNPs, we
used SNP array-derived data (Illumina OMNI Chip) of 473 Italian PEX patients
(421 with age and gender information) and 1,545 healthy individuals (1,505 with
age and gender information) from an Italian population-based control cohort
(Hypergene) as well as 1,484 Japanese PEX patients and 1,188 healthy individuals
from a Japanese population-based control cohort.
Genotyping and association analysis. Genotyping of German patients and
control subjects was performed on the Affymetrix Genome-Wide Human SNP
Array 6.0. Italian patients were genotyped on the Illumina OmniExpress Bead
Array-12 v.1.1, Italian control subjects on the Illumina 1M Duo. Stringent quality
checks for the German data set were performed on a per-SNP and per-sample
basis, with removal of SNPs showing a genotyping success rate of o95% or a
minor allele frequency of o1% as well as deviation from Hardy–Weinberg
equilibrium (Po1 10 3 for deviation). Samples were similarly checked, and
those with a genotyping success rate of o97% were removed. A principal
component analysis performed with EIGENSTRAT version 3.0 had shown that
German and Italian PEX cases and controls appeared to be well matched in terms
of ancestry as well as in overall assessment (Supplementary Figs 12 and 13).
Quality control criteria for Japanese and Italian data sets have been described
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previously64. Both German and Italian genotypes were imputed into the 1,000
genomes data set (March 2012 haplotypes) using IMPUTE2 (ref. 68). Association
analyses on the imputed data were performed with SNPTEST v2.5.2 (ref. 69).
A logistic regression model using gender and age as covariates in German and
Italian samples and the ﬁrst six principal components of genetic stratiﬁcation in
Japanese as previously described22,64 was used to determine the per-allele, additive
effect of the SNPs with a score-based, frequentist algorithm in SNPTEST2. By
adding the dosages of rs3825942 and rs1048661 as additional covariates, we tested
for independence of our 14 associated SNPs from the two SNPs (rs3825942 and
rs1048661) of the original published locus. Regional association plots were created
using LocusZoom version 1.1 (ref. 70). Statistical analysis for quality control, w2 test
of association, logistic regression for adjustment of P values and multi-dimensional
scaling for population stratiﬁcation were performed using PLINK version 1.07
(ref. 71). The German and Italian haplotypes were estimated by PHASE version
2.1 (ref. 72). P values and odds ratios (ORs) of different haplotypes were calculated
with w2-based tests using PLINK version 1.07.
Human tissues. Human donor eyes used for corneal transplantation with
appropriate research consent were obtained from Caucasian donors and processed
within 20 h after death. Informed consent to tissue donation was obtained from the
donors or their relatives, and the protocol of the study was approved by the
Ethics Committee of the Medical Faculty of the Friedrich-Alexander-Universita¨t
Erlangen-Nu¨rnberg (No. 4218-CH) and adhered to the tenets of the Declaration of
Helsinki for experiments involving human tissues and samples.
For RNA and DNA extractions, 52 donor eyes with manifest PEX syndrome
without (n¼ 43) or with (n¼ 9) glaucoma (mean age, 81.1±7.5 years; 32 female,
20 male) and 51 normal appearing age-matched control eyes (mean age, 76.3±10.2
years; 23 female, 28 male) without any known ocular disease were used. For protein
extractions, another 20 donor eyes without any known ocular disease (mean age,
74.3±5.54 years; 11 female, 9 male) were used. The presence of characteristic PEX
material deposits was assessed by macroscopic inspection of anterior segment
structures and conﬁrmed by electron microscopic analysis of small tissue sectors.
Ocular tissues (Tenon’s capsule, cornea, trabecular meshwork, iris, ciliary body,
retina, choroid, lamina cribrosa and sclera) were prepared under a dissecting
microscope and shock frozen in liquid nitrogen. Specimens of aortic wall were
obtained at autopsy within 24 h after death from ﬁve organ donors with PEX
syndrome (mean age, 71.6±3.5 years) and ﬁve age-matched subjects without PEX
(mean age, 68.3±7.7 years).
Genotyping of human tissues and cells. DNA samples obtained from ocular
tissues and cells were genotyped by Sanger sequencing. Primers surrounding the 14
intronic SNPs, rs8023330, rs1550436, rs2165241, rs28588430, rs28617339,
rs4886778, rs8027022, rs2028386, rs4337252, rs12440667, rs12905253, rs11638944,
rs12441130 and rs11631579, and the two exonic SNPs, rs1048661 and rs3825942 of
the LOXL1 gene were designed using Primer3 software (http://frodo.wi.mit.edu/
cgi-bin/primer3/primer3_www.cgi/) and supplied from Thermo Scientiﬁc
(Schwerte, Germany) (Supplementary Table 3.1). Puriﬁed PCR fragments were
sequenced using Big Dye Termination chemistry v.3.1 (Applied Biosystems, ABI,
Weiterstadt, Germany) on an automated capillary sequencer (ABI 3730 Genetic
Analyzer). All sequences were analysed using Sequencer5.1 (Gencodes) software
and compared with the respective reference SNP sequences from the human
genome sequence (hg19).
Real-time PCR. Ocular tissues and cultured cells were extracted using the Precellys
24 homogenizer and lysing kit together with the AllPrep DNA/RNA kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions including an
on column DNaseI digestion step using the RNase-free DNase Set (Qiagen).
First-strand cDNA synthesis from 0.5 mg of total RNA was carried out using
200U Superscript II reverse transcriptase (Thermo Scientiﬁc) and 200 ng of
random primers (Roche Life Science, Mannheim, Germany) in a 20 ml reaction.
Quantitative real-time PCR was performed using the CFX Connect thermal cycler
and software (Bio-Rad Laboratories, Mu¨nchen, Germany). PCR reactions (25ml)
were run in duplicate and contained 2 ml of ﬁrst-strand cDNA, 0.48 mM each of
upstream- and downstream-primer, and SsoFast EvaGreen Supermix (Bio-Rad).
Exon-spanning primers (Euroﬁns Genomics, Ebersberg, Germany), designed by
means of Primer 3 software (available at: http://bioinfo.ut.ee/primer3/, accessed
November 3, 2014), and PCR conditions are summarized in Supplementary
Table 3.2. For quantiﬁcation, serially diluted standard curves of plasmid-cloned
cDNA were run in parallel, and ampliﬁcation speciﬁcity was checked using
melt curve and sequence analyses with the Prism 3100 DNA-sequencer (Applied
Biosystems). For normalization of gene expression levels, mRNA ratios relative to
the house-keeping gene GAPDH were calculated.
Western blot analysis. Total protein was extracted from iridal tissue specimens
using the PRECELLYS24 tissue homogenizer (Bertin Instruments, Montigny-le-
Bretonneux, France) and RIPA buffer (50mM Tris-HCl pH 8.0, 150mM NaCl,
1% NP-40, 0.5% DOC, 0.1% SDS) containing protease inhibitor cocktail
(Sigma-Aldrich, Saint Louis, MO). Protein concentrations were determined by the
Micro-BCA protein assay kit (Thermo Scientiﬁc). Proteins (10mg per lane) were
separated by 4–15% SDS–polyacrylamide gel electrophoresis under reducing
conditions (1 sample buffer: 75mM Tris-HCl pH6.8, 2% SDS, 10% glycerol,
0.002% bromphenol blue, 100mM DTT) and transferred onto nitrocellulose
membranes (Bio-Rad) with the Trans-Blot Turbo transfer system (Bio-Rad)
according to the manufacturer’s recommendations. Membranes were blocked with
SuperBlock T20 (Thermo Scientiﬁc) for 30min and incubated for 1 h at room
temperature with antibodies against LOXL1 (1 mgml 1; kindly provided by
Takako Sasaki, Erlangen), RXRa (2mgml 1; clone D-20, sc-553, Santa Cruz,
Heidelberg, Germany) and -actin (0.5 mgml 1; clone AC-15, A5441, Sigma-
Aldrich) diluted in PBST-10% SuperBlock T20 (phosphate buffered saline pH 7.4,
0.1% Tween-20, 10% SuperBlock T20). In negative control experiments, the
primary antibody was replaced by PBS. Immunodetection was performed with a
horseradish peroxidase-conjugated goat anti-rabbit (31460, Thermo Scientiﬁc) or
goat anti-mouse (405306, Biolegend, Fell, Germany) secondary antibody diluted
in PBST-10% SuperBlock T20 at a ﬁnal concentration of 5 ngml 1, and the
Super Signal West Femto (LOXL1 and RXRa) or Pico (-actin) ECL kit
(Thermo Scientiﬁc). Speciﬁc protein bands were quantitatively analysed with
the LAS-3000 (Fujiﬁlm, Du¨sseldorf, Germany) chemiluminescence detection
system and software (Multi Gauge V1.1, Fujiﬁlm). For normalization of LOXL1
protein expression levels, protein ratios relative to the house-keeping gene -actin
were calculated.
Plasmid construction. The LOXL1 minimal promoter region was ampliﬁed as a
1,636 bp DNA fragment using the HotStar HiFidelity DNA polymerase (Qiagen)
with primers and conditions as speciﬁed in Supplementary Table 3.3.
Digestion with HindIII/NcoI resulted in a LOXL1 promoter fragment
(73,925,346–73,926,784, NC_000015) extending from  1438 bp to the ATG start
codon (þ 1) (ref. 35), which was cloned into the pGL4.10[luc2] reporter vector
(Promega, Mannheim, Germany) via HindIII/NcoI resulting in a pGL4.10-LOXL1
construct.
To determine the inﬂuence of selected SNPs (1: rs8023330A4G, 2:
rs1550436C4T, 3: rs2165241C4T, 4: rs28588430G4C, 5: rs28617339C4T,
6: rs4886778A4C, 7: rs8027022A4G, 8: rs2028386G4C, 9: rs4337252C4G,
10: rs12440667C4T, 11: rs12905253G4A, 12: rs11638944C4G, 13:
rs12441130T4C and 14: rs11631579A4G) on LOXL1 promoter activity, synthetic
DNA fragments (Euroﬁns Genomics) harbouring the risk alleles (14sR) or the non-
risk alleles (14sN) of all 14 SNPs [EcoRV-Bgl II-SNPs1 to 14-Bgl II-HindIII] were
cloned into pGL4.10-LOXL1 via EcoRV/HindIII upstream of the LOXL1 promoter
resulting in pGL4.10-LOXL1-14sR/N constructs (Fig. 5a). The DNA ﬂanking
sequences surrounding each of the 14 SNPs consisted of 51 bp of genomic DNA
sequence (NC_000015) with each SNP in the center. The basal LOXL1 promoter
construct was prepared by restriction of pGL4.10-LOXL1-14sR with Bgl II.
Synthetic DNA fragments containing risk and non-risk alleles, respectively,
[EcoRV-EcoRI-SNPs 1 to 5-EcoRI-NdeI-SNPs 6 to 10-NdeI-Bgl II-SNPs 11 to
14-Bgl II-HindIII] were subsequently cloned into the EcoRV/HindIII sites of
pGL4.10-LOXL1, and digested with EcoRI, NdeI, and Bgl II, respectively, to obtain
deletion constructs pGL4.10-LOXL1-14sR/N1-5, -14sR/N6-10 and -14sR/N11-14.
Genomic sequences (228–292 bp) including single SNPs with 50-KpnI and 30-Bgl II
(SNPs 11, 12 and 14) or 50-KpnI and 30-BamHI (SNP 13) restriction sites,
respectively, were ampliﬁed by PCR with primers speciﬁed in Supplementary
Table 3.3 and cloned into the basal LOXL1 promoter construct via KpnI/Bgl II
resulting in pGL4.10-LOXL1-11R/N, -12R/N, -13R/N and -14RN constructs.
Digestions were carried out with enzymes from NEB (Frankfurt, Germany),
ligations with the Rapid DNA Dephos & Ligation kit (Roche), and plasmid
preparations with the Nucleobond Xtra Maxi EF kit (Macherey-Nagel, Du¨ren,
Germany). Conﬁrmatory sequencing was carried out for all constructs (Euroﬁns
Genomics). All sequences of pGL4.10 constructs and the plasmids themselves are
available upon request.
Cell culture and dual luciferase reporter assays. Tenon’s capsule biopsies were
obtained from ﬁve German patients with PEX syndrome (mean age, 78.3±10.5
years) and from 25 age-matched patients without PEX (mean age, 73.0±5.4 years)
during cataract surgery. In addition, ten biopsy samples were obtained from
younger German patients (mean age, 18.2±6.4 years) during vitreoretinal surgery,
and from six Japanese patients without PEX (mean age, 66.3±4.5 years) during
pterygium surgery. Informed consent to tissue donation was obtained from the
patients, and the protocol of the study was approved by the Ethics Committee of
the Medical Faculty of the Friedrich-Alexander-Universita¨t Erlangen-Nu¨rnberg
(No. 4218-CH) and the Institutional Review Board Committee of Ozaki Eye
Hospital (No. 16). The experiments adhered to the tenets of the Declaration of
Helsinki for experiments involving human tissues and samples.
Primary hTCF cultures were established from Tenon’s capsule biopsies and
maintained in Dulbecco´s modiﬁed Eagle´s medium (DMEM/Ham´s F12; Invitrogen,
Darmstadt, Germany) containing 15% (v/v) fetal bovine serum (FBS) and
antibiotic-antimycotic solution (PSA; Invitrogen) at 37 C in a humidiﬁed 95%
air–5% CO2 atmosphere. Primary hONHA cultures were generated from lamina
cribrosa tissue of ﬁve normal donor eyes (mean age, 63.7±9.5 years) and
maintained in DMEM/Ham’s F12 with 10% FBS, 1% PSA, supplemented with
5 ngml 1 bFGF and 5 ngml 1 PDGF-AA (Sigma-Aldrich), in a 95% air–5% CO2
humidiﬁed atmosphere at 37 C. Primary hLEPC cultures were generated from
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corneoscleral donor tissue (n¼ 5; mean age, 64.7±7.3 years) with appropriate
research content provided by the Erlangen Cornea Bank after corneal endothelial
transplantation and maintained in Keratinocyte serum free medium (Invitrogen)
supplemented with bovine pituitary extract, epidermal growth factor and PSA.
Primary hTMC from three different donors were obtained from Provitro
(Berlin, Germany) and grown in DMEM supplemented with 10% FBS and 1% PSA.
Primary hASMC were also obtained from Provitro and grown in SMCM medium
(Provitro). For transfection experiments, primary cells were used at passages 3–4.
The immortalized hNPEC line ODM-2 was kindly supplied by Miguel
Coca-Prados (Fundacio´n de Investigacio´n Oftalmolo´gica, Oviedo, Spain), grown in
DMEM (with 4.5 g l 1 glucose) supplemented with 10% FBS and 50 mgml 1
gentamycin, and was used up to passage 12. HEK293T cells and the mouse
embryonic ﬁbroblast 3T3 cell line were obtained from ATCC (Manassas, VA)
and grown in DMEM (with 4.5 g l 1 glucose) supplemented with 10% FBS
and 1% PSA.
Cells (1.0 06) were transiently transfected by electroporation using the
Nucleofector II transfection device (Lonza, Ko¨ln, Germany) and the Amaxa Basic
Fibroblasts Nucleofector kit (Lonza) for hTCF, hTMC, hONHA, hASMC and 3T3
cells or the Amaxa Cell Line V Nucleofector kit for hNPEC, and hLEPC, and 6 mg
pGL4.10-LOXL1 reporter construct together with 0.9 mg Renilla luciferase plasmid
pGL4.74 (Promega). Nucleofector programs used were U-023 for hTCF, hTMC,
hONHA, hNPEC and 3T3 cells, U-025 for hASMC and V-023 for hLEPC.
Transfected cells were seeded into six-well plates in triplicate. HEK 293 T cells were
seeded in six-well plates at a density of 2.5 105 cells per well and transfected in
triplicate with 0.5 mg pGL4.10-LOXL1 reporter construct together with 0.1 mg
pGL4.74 using Lipofectamine LTX (Thermo Scientiﬁc) according to the
manufacturer’s recommendations. At 24 h post-transfection, cells were washed
with PBS and lysed using Glo Lysis Buffer (Promega).
LOXL1 promoter activity of cell extracts was assayed using the Dual-Glo
Luciferase Assay System (Promega), and luminescence was measured on a GloMax
luminometer (Promega). To correct for transfection efﬁciency, luciferase reporter
construct activity was normalized to Renilla luciferase activity, and results are
expressed as the ratio of Fireﬂy luciferase [luc2] to Renilla luciferase. Data represent
at least ﬁve independent experiments for each cell type analysed.
In different sets of experiments, cells were co-transfected with RXRa-speciﬁc
siRNA (see below) or stimulated with all trans-retinoic acid (Sigma-Aldrich) at a
concentration of 2 mM for 48 h.
Allele-speciﬁc expression analysis. hTCF cell lines (n¼ 15) heterozygous for the
risk and non-risk alleles of LD-SNPs 11–14 were analysed using a predesigned
TaqMan SNP Genotyping Assay for SNP 13 (rs12441130T4C) (C_30687884_10,
Applied Biosystems) to compare the relative allelic expression of LOXL1 pre-
mRNA. Real time PCR based SNP detection was performed using 2 ml of cDNA
preparation transcribed with random primers in a QuantStudio 12K Flex
Real-Time PCR System machine (Applied Biosystems) according to the manu-
facturer’s instructions. The detection difference of the two alleles was normalized
using genomic DNA from each donor. The relative expression of the disease-
associated allele compared with the other allele was analysed in triplicates and
determined using the DDCt method. Genomic DNA and pre-mRNA from cell lines
known to be homozygous for the risk (n¼ 4) or non-risk alleles (n¼ 4) of these
SNPs was included as a reference.
Chromatin immunoprecipitation. ChIP experiments were performed on hTCF
cell lines (n¼ 2) heterozygous for the risk and non-risk alleles of LD-SNPs
rs12905253, rs11638944, rs12441130 and rs11631579 using antibodies against RNA
polymerase II (Santa Cruz, sc-899) or antibodies against RXRa (Santa Cruz, sc-553:
clone D-20 and sc-46659: clone F-1). Antibodies against histone H3 (Abcam,
Cambridge, UK, ab1791) and acetylated histone H3K27Ac (Diagenode, Denville,
NJ, pAb-174-050) were used as positive controls and normal rabbit IgG
(Merck Millipore, Darmstadt, Germany, 12-370) as negative control. Brieﬂy,
cells were grown in 15 cm dishes to about 80% conﬂuency before being subjected to
1% formaldehyde for 12min at 4 C to crosslink protein complexes to DNA. Cross
linking was quenched by addition of 125mM glycine. Cells were lysed using ChIP
lysis buffer (1% SDS, 10mM EDTA, 50mM Tris, 40 ml ml 1 cOmplete protease
inhibitor cocktail) (Sigma-Aldrich). Cell lysates were sonicated in 15 s pulses for a
total of 14min (Diagenode, Bioruptor Plus sonication device), diluted with ChIP
dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris,
167mM NaCl), and precipitated with 2 mgml 1 antibodies and 25% protein A
agarose (Merck Millipore). After incubation and centrifugation, the pellet was
resolved in low-salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris,
150mM NaCl) and washed in high-salt buffer (0.1% SDS, 1% Triton X-100, 2mM
EDTA, 20mM Tris, 500mM NaCl), LiCl buffer (0.25 M LiCl, 1% Igepal,
1% deoxycholate, 1mM EDTA, 10mM Tris) and TE buffer (1mM EDTA and
10mM Tris). ChIP elution buffer (0.0841 g NaHCO3, 1% SDS) was used to resolve
chromatin antibody binding. To break up cross-links between proteins and DNA,
probes, samples were sequentially incubated in 5M NaCl and in 0.5M EDTA, 1M
Tris and 40 mg Proteinase K. After phenol–chloroform extraction, the precipitated
DNA was dissolved in Nuclease-free H2O. Samples were analysed by qPCR using
the TaqMan SNP Genotyping Assay for SNP 13.
Splicing analysis. Alternative mRNA splicing was analysed in hTCF cell lines
homozygous for the risk (n¼ 8) or non-risk (n¼ 8) alleles of LD-SNPs 11–14 by
qPCR using primers designed for exon 1 and the additional exon 1A included in
the alternative LOXL1 transcript LOXL1-002 (LOXL1_E1A) (ENST00000566011;
www.ensembl.org) known to undergo NMD (Fig. 7a, Supplementary Table 3.3).
For inhibition of NMD, cells were treated with 200 ngml 1 puromycin
(Sigma-Aldrich) for 10 h.
Electrophoresis mobility (super)shift assays. A nuclear extraction kit (NE-PER
Nuclear and Cytoplasmic Extraction Reagents, Thermo Scientiﬁc) was used to
prepare cytoplasmic and nuclear extracts from primary hTCF, hTMC, hNPEC,
hLEPC, hASMC, HEK293T and 3T3 cells according to the manufacturer’s
instructions.
Biotinylated DNA probes were ampliﬁed by PCR using 50-biotinylated 20–23 bp
primers (Supplementary Table 3.3) (Euroﬁns Genomics) using tissue samples from
genotyped individuals homozygous for the risk and non-risk haplotypes as
templates. All binding reactions were carried out using the non-radioactive
LightShift Chemiluminescent EMSA Kit (Thermo Scientiﬁc) according to
manufacturer’s protocol. Brieﬂy, the binding reaction mixture (total volume 20 ml)
containing 2 ml of nuclear extract (at a concentration of B2 mgml 1) was
pre-incubated with 50 ngml 1 of poly [d(I-C)] in binding buffer (10mM Tris,
50mM KCl, 1mM DTT, pH 7.0) on ice for 10min. After addition of 20 fmol
biotin-labeled target DNA, the binding reaction was incubated at room
temperature for 20min. For competition experiments, a 200-fold molar excess
(4 pmol) of unlabelled oligonucleotides were included in the pre-incubation
mixture. Subsequently, all reactions were loaded onto a 4% (supershift) or
6% (EMSA) non-denaturing polyacrylamide gel and run for 1 h in 0.5 TBE
running buffer (45mM Tris, 45mM boric acid, 1mM EDTA, pH 8.3). After
electrophoresis, complexes were transferred to a positively charged nylon
membrane, ultraviolet crosslinked at 120mJ cm 2, probed with streptavidin-HRP
conjugate and incubated with enhanced chemiluminescence substrate (ECL;
Thermo Scientiﬁc). Gel shifts were quantitatively analysed with the LAS-3000
(Fujiﬁlm, Du¨sseldorf, Germany) chemiluminescence detection system and software
(Multi Gauge V1.1, Fujiﬁlm).
For supershift assays, 1 mg of antibodies against NFkB p50 (sc-7178X), NFkB
p65 (sc-7151X), PPARa (sc-9000X), PPARg (sc-7196X), NR2F1 (sc-6575X),
HNF-4a (sc-8987X), myogenin (sc-13137X), ROAZ (sc-514748X), NF1 (sc-74445),
RXRa (sc-46659X), RXRb (sc-742X), RXRg (sc-365252 X), RARa (sc-551X),
LXRa-b (sc-13068X), VDR ( sc-9164), TRa-b (sc-772X) and ERa (sc-8005X), all
purchased from Santa Cruz, and against ZID/ZBTB6 (ab67628) purchased from
Abcam was added to the reaction mixture and incubated at room temperature for
30min prior to addition of the biotinylated probe.
Recombinant proteins of full-length human RXRa (TP310311, OriGene,
Rockville, MD), DNA-binding domain (aa 11-228; pro-437, Prospec, Rehovot,
Israel) and ligand-binding domain (aa 198–462; 31135, Active Motif, Carlsbad,
CA) of RXRa as well as a RXR consensus oligonucleotide (sc-2547, Santa Cruz)
were used as positive controls.
siRNA silencing. hTCF (0.75 106) were transiently transfected with speciﬁc
siRNA (ON-TARGETplus SMARTpool, GE Healthcare Dharmacon, Freiburg,
Germany) for UPF1 (75 pmol; target sequences: CAGCGGAUCGUGUGAAGAA,
CAAGGUCCCUGAUAAUUAU, GCAGCCACAUUGUAAAUCA, GCUCGC
AGACUCUCACUUU) or RXRa (150 pmol; target sequences: GCGCCAUCGU
CCUCUUUAA, GCAAGGACCGGAACGAGAA, AGACCUACGUGGAGGC
AAA, UCAAAUGCCUGGAACAUCU) by electroporation using the Nucleofector
II transfection device (Lonza) and the Amaxa Basic Fibroblasts Nucleofector Kit
(Lonza) with the nucleofector programme U-023. Transfections with scrambled
siRNA (ON-TARGETplus Non-targeting pool, GE Healthcare Dharmacon) served
as controls. Transfected cells were seeded into six-well plates in duplicate and
collected at 48 h post transfection for real-time PCR analysis.
In silico analysis. The rSNP-MAPPER software tool (available at http://geno-
me.uﬂ.edu/mapper) was used to predict transcription factor binding sites affected
by the analysed SNPs37. The sequences of the vectors containing the risk or
non-risk alleles, respectively, were provided as input. Furthermore, predictions
were also obtained for the genomic regions of each single SNP. UCSC Genome
Browser (http://genome.ucsc.edu/) was used to visualize the analysed SNPs in the
genomic context and to explore results of ENCODE experiments to identify
regions with evidence of potential regulatory activity.
Statistical analysis. Group comparisons for the reporter assays, expression
analyses, and comparative allele representation were performed using an
unpaired two-tailed t-test or a Mann–Whitney U-test using SPSS v.20 software
(IBM, Ehningen, Germany). Po0.05 was considered statistically signiﬁcant.
Data availability. The genome-wide association SNP results are available upon
request by contacting Francesca Pasutto at Francesca.pasutto@uk-erlangen.de. Any
additional data (beyond those included in the main text and Supplementary
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Information) that support the ﬁndings of this study are also available from the
corresponding author upon request.
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